• Print
  •  

DISEASE:

ALK ALK
Transplantation Transplantation

CATEGORY:

ALK Rearrangement and Lung Cancer ALK Rearrangement and Lung Cancer
Diagnosis of ALK Rearrangement Diagnosis of ALK Rearrangement
ALK gene fusions, crizotinib, and NSCLC ALK gene fusions, crizotinib, and NSCLC

SPEAKER:

Susana R. Marino, MD, PhD, D (ABHI) Susana R. Marino, MD, PhD, D (ABHI)
Robert Doebele Robert Doebele
Marileila Varella-Garcia Marileila Varella-Garcia
William Hildebrand, PhD William Hildebrand, PhD
Mike Bunce, PhD Mike Bunce, PhD

EVENT:

2011 Association of Molecular Pathology Meeting 2011 Association of Molecular Pathology Meeting
ASHI ASHI
 
 

Below you will find information that will help enhance your clinical and molecular laboratory knowledge. This section will provide presentations led by prominent physicians, laboratory leaders, subject matter experts, and Abbott scientific professionals that will provide insight on molecular diagnostic trends, genetic and biomarker innovations, medical discoveries, health technologies, and more.

 
Disease Title Speaker Event
 
 
 
 
 
 

 

Targeting ALK Rearrangements
12-14-2011

Developments for Lung Adenocarcinoma Patients: Targeting ALK Rearrangements

Program Learning Objectives:

  • Learn about Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements in lung cancer
  • Discuss new testing methods for ALK Gene Rearrangement in lung cancer
  • Review guidelines for Xalkori® (crizotinib) and ALK testing relating to histology and timing of testing
  • Identify the appropriate selection of patients for Xalkori® (crizotinib)
  • Examine clinical trial results for Xalkori® (crizotinib) and overview of ongoing trials
Presented by:
Gregory Riely, MD, PhD Maureen Zakowski, MD
Assistant Attending
Memorial Sloan-Kettering Cancer Center
Attending Pathologist
Memorial Sloan-Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
Professor of Pathology and Laboratory Medicine
Weill Cornell Medical College 
New York, New York New York, New York


   
 
 
 

 

ALK Rearrangement and Lung Cancer
11-16-2011
Runtime: 26:13

Diagnosis of ALK Rearrangement by FISH in NSCLC

As presented at the 2011 Association of Molecular Pathology Meeting.

Presented by:
Marileila Varella-Garcia, PhD  
Professor of Medicine Education Program  
Leader, Cytogenetics Core Director  
University of Colorado, Denver  
School of Medicine , Division of Medical Oncology  
 
 
A CE-Accredited Webcast
10-19-2011

New Technology Opportunities in Solid Organ
Transplant Testing

You will need to view all four modules to obtain 1.0 contact hours of P.A.C.E.® (Professional Acknowledgment for Continuing Education) credit in addition to completing the
Evaluation and Verification of Participation forms. These may be emailed to rebecca.schingel@remedica.com or faxed to 312-993-1522.

Module 1

• Learning Objectives and Faculty Disclosures

• Management of Highly Sensitized Kidney Transplant Patients in the Context of State-of- the-Art HLA Testing Technologies

Presented by: Susana R. Marino, MD, PhD, D (ABHI)

Module 3

• Question and Answer Session (recorded at the 2011 Annual Meeting of The American Society for Histocompatibility and Immunogenetics, ASHI)

• How to Obtain CE Credit

Module 2

Current Challenges and Developments in HLA Immunoassay Reagents

Presented by: William Hildebrand, PhD

 

 

 
 
 

Seo